NJ-TRUE
19.4.2022 08:05:10 CEST | Business Wire | Press release
True , the fastest-growing global platform of innovative talent management products and services, announced today it has appointed Kate Vanek as general manager, international. Kate joins True from BlackRock where she held the dual responsibility of CFO of EMEA and COO of global finance.
In her role, Kate will work closely with True’s global leadership to enhance and expand the firm’s international executive search business and broader platform of talent management products and services including Thrive, Synthesis, and AboveBoard. Kate is London-based and will oversee the international business across EMEA and APAC, which today includes True's offices in Amsterdam, Berlin, Dubai, London, Melbourne, Shanghai, Singapore, Stockholm, Sydney and Tel Aviv.
“Kate has a passion for talent management and a dynamic, inspirational leadership style,” said Joe Riggione , True co-founder and co-CEO. “She’s a high-performance operator who combines her personal and business experiences to connect people and complex global organizations. She is an impressive leader with an extraordinary track record, and we are lucky to have her.”
“I’m thrilled to be joining True during this period of expansion, and I’m excited to help propel True’s vision to build the global talent management firm of the future,” Kate commented. “True’s special culture and commitment to investing in its people, combined with their world-class executive search expertise and cutting-edge platform make it a place I couldn’t be more proud to join.”
“Kate's experience in strategic business building prepares her to expand our offerings globally to meet the needs of our clients who rely on True’s talent expertise and platform to help them grow and thrive,” said Brad Stadler , True co-founder and co-CEO.
Kate Vanek, True’s GM, International
Kate’s background has rich diversity of experience in finance, strategy and business operations, M&A, investor relations, DE&I initiatives, and leadership development. She has managed global teams in leadership roles across a range of industries from financial services, data science, consumer behavior measurement to industrials.
ABOUT TRUE
True is a platform of products and services driving the intelligence behind talent management:
True Search
Global recruitment for board members, c-suite executives, VPs, directors, and other strategic talent. We focus on investment firms, their portfolio companies and public companies seeking transformative growth.
Thrive
Collaborative, real-time talent relationship management software and information services for search firms, in-house recruiters and VC/PE firms looking to make better hiring decisions.
Synthesis
A multi-layered approach to leadership assessment and development, which combines the evaluation methods of elite military units, executive coaching techniques and agile methodology principles.
AboveBoard
True co-founded AboveBoard, a diversity-focused startup bringing unparalleled solutions to the critical need to bring more women and executives of color to leadership roles. With AboveBoard's two-way platform, members get unique visibility to hundreds of opportunities while companies get access to qualified candidates.
True Equity
True Equity provides exposure to high-quality venture capital and growth equity investments. As a value-added talent partner, True Equity makes direct investments alongside premier investors. True Equity Fund I participates in Series A and B investments. True Equity Growth Fund II focuses on late stage venture and growth equity companies.
Vera
Vera is a family of investment funds that backs exceptional entrepreneurs and companies dedicated to changing our collective future through technology at the pre-seed, seed, early, and late stages.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220418005587/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
